GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares. The London-based company’s announcement comes on the heels of the U.S. Drug Enforcement Administration’s move to take some cannabidiol products off the most restrictive class of controlled substances. That change will allow Epidiolex – a CBD drug manufactured by GW Pharmaceuticals to treat rare […]
This post is from Marijuana Business Daily. We encourage our readers to continue reading the full article from the original source here.